View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
December 21, 2017updated 03 Jan 2018 11:40am

A look at Amgen’s top performing drugs

Enbrel and Neulasta are the best performing drugs by a large margin; however, many of their other drugs are also top performers.

By GlobalData Healthcare

Figure 1: Top 10 Selling Products of Amgen (US$ mill)

Source: GlobalData, Pharma Intelligence Center, [Accessed 19th Dec 2017]

Figure 1 displays the sales values of the top ten products of Amgen for 2016. Enbrel and Neulasta are the best performing drugs by a large margin; however, many of their other drugs are also top performers. There top 7 drugs all make over 1,000 (US$m). Going forward Enbrel and Neulasta revenues are expected to half by 2023 meaning Amgen position may not be as strong going forward, but Amgen are expecting another high performing drug in Repatha; expected to be valued at 3,440 (US$m) by 2023.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology